CymaBay Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$191.5M
Lead Investor(s):Leerink Partners LLC, Evercore ISI

Estimated Revenue & Financials

  • CymaBay Therapeutics's estimated annual revenue is currently $6.8M per year.(?)
  • CymaBay Therapeutics received $Undisclosed in venture funding in January 2018.
  • CymaBay Therapeutics's estimated revenue per employee is $128,943
  • CymaBay Therapeutics's total funding is $191.5M.

Employee Data

  • CymaBay Therapeutics has 53 Employees.(?)
  • CymaBay Therapeutics grew their employee count by 10% last year.
  • CymaBay Therapeutics currently has 5 job openings.

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPAR agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH). For additional information about CymaBay visit

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power